Introduction: Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system which affects young people, especially women. The aim of the study was to examine the disease profile of MS during pregnancy and postpartum as well as pregnancy outcomes in women with MS compared to a control group. Such a study has not been conducted in Iceland before.
Material And Methods: A hospital based retrospective study with data from the Icelandic Medical Birth Register and medical records from Landspitali University Hospital including women with MS diagnosis during 2009-2018 and their deliveries through 1999-2018, a total of 91 women and 137 births.
Results: Relapse frequency decreased during pregnancy compared to the preceding year. Over half of the women received disease modifying drugs before pregnancy, all stopped treatment before or shortly after conception. Women in the study group underwent cesarean sections before labor more frequently than the control group. The gestational length was comparable between the groups when labor was spontaneous. The numbers of heavy- and lightweight newborns as well as Apgar scores were alike in both groups.
Conclusion: We believe that our study reflects actual pregnancy outcome among Icelandic women with MS and our results show that their pregnancies and deliveries do not differ in any major aspect from the general population. Our findings agree with previous studies in that pregnancy protects against MS relapses although in our study this is confined to the first and second trimester.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.17992/lbl.2020.12.612 | DOI Listing |
Cancer
February 2025
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Background: The risk of recurrence in patients with small, lymph node-negative, human epidermal growth factor receptor 2 (HER2)-positive breast cancers untreated with adjuvant chemotherapy/HER2-directed therapy is uncertain. To investigate this, the authors conducted a retrospective, population-based study of chemotherapy use and breast cancer-specific survival (BCSS) among patients with stage IA HER2-positive breast cancer.
Methods: The authors analyzed Surveillance, Epidemiology, and End Results data from patients diagnosed with stage IA HER2-positive breast cancer from 2010 to 2019.
Int J Cancer
January 2025
Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, Heidelberg, Germany.
Colorectal cancer (CRC) is the second overall leading cause of cancer death in the United States, with recurrence being a frequent cause of mortality. Approaches to improve disease-free survival (DFS) are urgently needed. The gut microbiome, reflected in fecal samples, is likely mechanistically linked to CRC progression and may serve as a non-invasive biomarker.
View Article and Find Full Text PDFTechnol Cancer Res Treat
January 2025
Department of Respiratory Medicine, Yantai Affiliated Hospital, Yantai Yuhuangding Hospital, Qingdao University, Yantai, P.R. China.
Background: Small cell lung cancer is sensitive to chemotherapy and radiotherapy, but local recurrence and distant metastasis occur shortly after treatment. This study aimed to evaluate the real-world value of anlotinib as a maintenance therapy in patients with extensive-stage small cell lung cancer (ES-SCLC) after first-line chemotherapy and consolidative thoracic radiotherapy (CTRT).
Patients And Methods: A total of 150 patients with ES-SCLC treated with first-line chemotherapy and CTRT from April 2017 to December 2021 were retrospectively analyzed.
Ann Acad Med Singap
December 2024
Department of Haematology, Singapore General Hospital, Singapore.
Introduction: Allogeneic haematopoietic stem cell transplantation (allo-HSCT) is a curative option for relapse/refractory (R/R) lymphomas that have failed autologous transplantation or for high-risk lymphomas in the upfront setting. We conducted a retrospective analysis on consecutive lymphoma patients who underwent allo-HSCT over a 20-year period (2003- 2022) at Singapore General Hospital and National University Hospital Singapore.
Method: A total of 121 patients were included in the study.
Acta Oncol
January 2025
Department of Oncology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Background And Purpose: Active surveillance is a recommended management strategy for patients with clinical stage I (CSI) seminoma. This study aims to identify patterns of relapse detection methods in an unselected population-based cohort of CSI patients and provide evidence for a risk-adapted follow-up program.
Patients/materials And Methods: A total of 924 patients with CSI seminoma were identified in the prospective Danish Testicular Cancer database.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!